Risk factors
Organogenesis Holdings (ORGO) risk factors
Item 1A of every Organogenesis Holdings Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors77 risks6 new6 dropped11 reworded
Organogenesis highlights new FDA regulatory risks for human cell and tissue products like Affinity, Novachor, and NuShield.
Filed Feb 26, 2026 - FY2024 10-K risk factors77 risks
Organogenesis Holdings Inc. faces concentration risks around reimbursement, human tissue supply, complex manufacturing, and stringent FDA regulation for its skin substitutes and wound care products.
Filed Feb 27, 2025